Idiotype of tumor immunoglobulin

The idiotype of tumor immunoglobulin refers to the unique collection of antigenic determinants (idiotopes) present in the variable region of the immunoglobulin expressed by an individual patient’s B cell tumor clone[1][2][5][6]. This idiotype arises from the specific amino acid sequences—primarily in the complementarity-determining regions (CDRs)—that are the result of somatic gene rearrangement and hypermutation during B cell development[2]. The idiotype constitutes a powerful, tumor-specific antigen (TSA) since each B cell malignancy expresses a clonally restricted, unique idiotype on its surface immunoglobulin, making it a true marker of the cancerous clone[1][2]. Therapeutically, targeting the idiotype—by either vaccination to stimulate anti-tumor immune responses or generating monoclonal antibodies against the idiotype—has been extensively explored in B cell lymphomas and multiple myeloma[1][4]. However, such approaches are hampered by the requirement for fully individualized reagent design and manufacture, as the idiotype is unique to each patient’s tumor. The idiotype can also serve as a minimal residual disease biomarker in B cell cancers[1]. Importantly, the term "idiotype of patient's tumor immunoglobulin" is not a single defined molecular entity or canonical protein, but a descriptor for a patient-specific tumor immunoglobulin variant; thus, it is not a standard, unified therapeutic target but rather a category of unique, patient-specific immunoglobulin determinants. This makes the entry structurally and ontologically incorrect as a standardized therapeutic target[1][2].

Other names

Tumor immunoglobulin idiotypeImmunoglobulin idiotypeIdiotype (Id)

Active immunization (idiotype vaccines induce anti-tumor immune response) Passive immunization (anti-idiotype antibodies mediate tumor cell killing via ADCC and CDC)